Thursday 29th November 2018 |
Text too small? |
Gentrack says it’s cautious about how Brexit will affect its business in Britain and Europe in the short-term, even though it remains confident it can grow organic operating earnings at 15 percent or more in the long term.
The company’s shares fell as low as $6.08, and were recently down 57 cents at $6.15, or 7.5 percent, from Wednesday’s close after it reported annual results in line with guidance, including a 17 percent increase in net profit to $13.9 million.
Chief executive Ian Black told analysts on a conference call that it is realistic and appropriate to note the potential impact of Brexit.
“Given that some of the energy suppliers are owned by European organisations, that means that there’s going to be a bit of caution about making decisions rapidly in the next short while until things settle down,” Black said.
“We’re just calling out that we, as much as anybody else, want to see the outcome of that Brexit decision and the potential impact on confidence in the UK and European markets,” he said.
“The mere fact that our platform is very sticky and is mission critical for our customers, means that the continued underlying spend on software and our support services and regulatory compliance activities will go on regardless of the political uncertainty,” he said.
“We’re just being cautious because we’re still dependent on projects and contracts to grow our business.”
The business in Britain is “very solid” with a broad customer base from tier one electricity companies to new entrants and delivers a very strong recurring revenue stream, Black said.
Britain accounted for 53.8 percent of Gentrack’s $104.5 million in revenue in the year ended September, up from just 30.8 percent the previous year.
As well, total committed annualised revenue more than doubled to $51.8 million.
“We added 25 utilities and three airport customers during the year, lifting full-year subscription and software licence revenues by 78 percent on last year to $48.9 million,” Black said.
“We have maintained our leading market share of the UK’s independent energy suppliers and our software has now been selected by a number of the largest utilities in the UK including Npower, E.ON and SSE,” he said.
Gentrack is in the process of transitioning its business from selling upfront licences with recurring maintenance contracts to a cloud-based subscription, software-as-a-service, business model.
Comparing the two models, “we see the total life-time value to Gentrack over seven years being at least 50 percent greater,” Black said. “In reality, most of our customers stay with us much longer than that.”
The aftermath of Gentrack’s $99 million float in mid-2014 was marred by a profit downgrade by as much as 32 percent shortly after it listed on NZX, largely reflecting timing issues with contracts.
In the event, earnings were 7.8 percent lower than the prospectus forecast at $13 million and the Financial Markets Authority decided to take no action after investigating the situation, but that experience has doubtless made the company more cautious about forecasting.
Gentrack’s final dividend of 8.7 cents per share, which takes the annual payout to 13.7 cents, up 8 percent on the previous year, is based on the company’s current dividend policy of paying out 70 percent of net profit before amortisation.
Black said that policy could be subject to review. “The business has changed quite considerably since that was put in place.”
Gentrack has bought four businesses since March 2017, including the purchase of Evolve in June for $44.9 million, and its recent $90 million rights issue has left it with $50 million of undrawn debt.
(BusinessDesk)
No comments yet
December 27th Morning Report
FBU - Fletcher Building Announces Director Appointment
December 23rd Morning Report
MWE - Suspension of Trading and Delisting
EBOS welcomes finalisation of First PWA
CVT - AMENDED: Bank covenant waiver and trading update
Gentrack Annual Report 2024
December 20th Morning Report
Rua Bioscience announces launch of new products in the UK
TEM - Appointment to the Board of Directors